The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 05, 2019
Filed:
Nov. 28, 2016
Applicant:
Symphogen A/s, Ballerup, DK;
Inventors:
Mikkel Wandahl Pedersen, Alleroed, DK;
Ida K. Christensen, Copenhagen, DK;
Johan Lantto, Lund, SE;
Helle Jacobsen, Virum, DK;
Michael Kragh, Copenhagen, DK;
Assignee:
Symphogen A/S, Ballerup, DK;
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/32 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/32 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6845 (2017.08); A61K 47/6851 (2017.08); A61N 5/10 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/3015 (2013.01); C07K 16/3053 (2013.01); C07K 16/3069 (2013.01); C07K 16/40 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract
The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.